Sector ratings Charles River Laboratories International, Inc.

Stocks

Market Closed - NYSE 04:00:03 2026-09-18 pm EDT			5-day change	1st Jan Change
278.06 ^USD	-1.28%		-0.07%	+39.39%

Sep. 17	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
Sep. 17	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.27B		AA
LONZA GROUP AG	46.28B		AAA
IQVIA HOLDINGS INC.	43.85B		AAA
REVOLUTION MEDICINES, INC.	40.93B	-	B	-	-
BEONE MEDICINES AG	39.9B		-
CELLTRION, INC.	29.5B		A
MEDPACE HOLDINGS, INC.	17.09B		BBB
ASCENDIS PHARMA A/S	15.55B	-	-	-	-
EUROFINS SCIENTIFIC SE	15.22B		AA
TEMPUS AI, INC.	14.05B		A		-
ICON PUBLIC LIMITED COMPANY	12.66B		AAA
BIO-TECHNE CORPORATION	11.35B		AA
PHARMARON BEIJING CO., LTD.	10.89B		AA
GENSCRIPT BIOTECH CORPORATION	11.43B		AA		-
KYMERA THERAPEUTICS, INC.	9.79B	-	BBB	-	-
ABIVAX	9.1B	-	BBB	-	-
PROTAGONIST THERAPEUTICS, INC.	9.25B		BB		-
QIAGEN N.V.	8.96B		AAA
PRAXIS PRECISION MEDICINES, INC.	8.35B	-	B	-	-
ALKERMES PLC	7.28B		A
Average	18.74B		AA
Weighted average by Cap.			AA